¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Clinical and experimental hypertension."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • kidney ureter and bladder
    ÄáÆÏ¿ä°ü¹æ±¤´Ü¼øÃÔ¿µ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å¼º°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • sinusoidal hypertension
    ±¼Ç÷°ü°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾ÐÁõ
  • orthostatic hypertension
    ±â¸³°íÇ÷¾Ð
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • primary hypertension
    (¢¡essential hypertension) º»Å°íÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄ°íÇ÷¾Ð
  • rebound hypertension
    ¹Ýµ¿°íÇ÷¾Ð
  • red hypertension
    È«Á¶°íÇ÷¾Ð, ºÓÀº°íÇ÷¾Ð
  • renal hypertension
    ÄáÆÏ°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • stasis hypertension
    ¿ïÇ÷°íÇ÷¾Ð
  • ocular hypertension indicator
    ¾È±¸°íÇ÷¾ÐÁöÇ¥
  • anxious and fearful personality
    ºÒ¾È°øÆ÷ÀΰÝ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypertension cranienne ºÒ
    ³ú¾ÐÇ×Áø(Áõ).
  • hypertension paroxystique ºÒ
    ¹ßÀÛ¼º °íÇ÷¾Ð(Áõ)(Û¡íÂàõÍÔúìäâñø).
  • hypertension,benign nephrosclerosis
    ¾ç¼º ½Å°æÈ­Áõ
  • hypertension,essential
    º»Å¼º(Üâ÷¾àõ)
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • hypertension,portal
    ¹®¸Æ¼º(Ú¦Øæàõ)
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ(Ú¦Øæäâùñòäñø), ¹®¸Æ°íÇ÷¾Ð(¡­ÍÔúìäâ).
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ(Ú¦Øæäâùñòäñø), ¹®¸Æ°íÇ÷¾Ð(Ú¦ØæÍÔúìäâ)
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ (¡­ÍÔúìäâñø).
  • primary hypertension
    ¿ø¹ß(¼º) °íÇ÷¾ÐÁõ(ê«Û¡(àõ) ÍÔúìäâñø)
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(¡­øËÍÔúìäâñø).
  • primary pulmonary hypertension
    ¿ø¹ß(¼º) Æó°íÇ÷¾ÐÁõ(ê«Û¡(àõ) øËÍÔúìäâñø)
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, Æó°íÇ÷¾ÐÁõ.
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð(øËÔÑØæÍÔúìäâ), Æó°íÇ÷¾ÐÁõ(øËÍÔúìäâñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð(¡­ÍÔúìäâ).
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð.
  • essential hypertension
    º»Å¼º(Üâ÷¾àõ)°íÇ÷¾Ð(ÍÔúìäâ)
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâñø), ±äÀåÇ×Áø(Áõ)(ÑÌíåùñòäñø).
  • hypertension
    °íÇ÷¾Ð(Áõ)(ÍÔúìäâ)
  • hypertension cranienne ºÒ
    ³ú¾ÐÇ×Áø(Áõ).
  • hypertension paroxystique ºÒ
    ¹ßÀÛ¼º °íÇ÷¾Ð(Áõ)(Û¡íÂàõÍÔúìäâñø).
  • hypertension,benign nephrosclerosis
    ¾ç¼º ½Å°æÈ­Áõ
  • hypertension,essential
    º»Å¼º(Üâ÷¾àõ)
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • hypertension,portal
    ¹®¸Æ¼º(Ú¦Øæàõ)
  • intracranial hypertension
    µÎ°³³»°íÇ÷¾Ð (¡­ÍÔúìäâ).
  • juvenile hypertension
    ¿¬¼Ò¼º °íÇ÷¾Ð(Áõ).
  • kallikrein-kinin,renal hypertension
    ½Å¼º°íÇ÷¾Ð(½Å¼º ÍÔúìäâ)
  • labile hypertension
    ºÒ¾ÈÁ¤¼º °íÇ÷¾Ð (¡­ÍÔúìäâ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Muscles of palate and fauces
    ÀÔõÀå ¹× ¸ñ±¸¸Û±ÙÀ°
    [¿¾ ¿ë¾î] ±¸°³±Ù ¹× ±¸Çù±Ù
  • Mode and course of progress
    ÁøÇà¾ç½Ä ¹× °úÁ¤
    [¿¾ ¿ë¾î] ÁøÇà¾ç½Ä¹×°úÁ¤
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • kidney ureter and bladder [=KUB]
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • KUB [=kidney, ureter and bladder]
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • PACS [=picture archiving and communicating system]
    ÆÑ½º, ¿µ»óÀúÀå ¹× Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • R & F [=radiography and fluoroscopy]
    ¹æ»ç¼±ÃÔ¿µ ¹× Åõ½Ã±â
  • salt and pepper appearance
    ¼Ò±ÝÈÄÃß°¡·ç¸ð¾ç
  • SONAR [=Sound Navigation and Ranging]
    ¼Ò³ª
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IPH idiopathic portal hypertension; idiopathic pulmonary hemosiderosis; idiopathic pulmonary hypertensio...
PHT phenytoin; portal hypertension; primary hyperthyroidism; pulmonary hypertension
PPH past pertinent history; persistent pulmonary hypertension; phosphopyruvate hydratase; postpartum hem...
STOP Study of Hypertension in the Elderly [Sweden] or Swedish Trial in Old Patients with Hypertension; su...
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
E Experimental
EAE Experimental Allergic Encephalitis
EAE Experimental Allergic Encephalomyelitis
EAN Experimental Allergic Neuritis
EAE Experimental Autoimmune Encephalomyelitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • primary hypertension
    ¿ø¹ß °íÇ÷¾ÐÁõ, ¿ø¹ß¼º °íÇ÷¾ÐÁõ
  • pulmonary arterial hypertension
    Æó ¼øÈ¯ ½Â¾Ð
  • pulmonary hypertension
    Æó ¼øÈ¯ ½Â¾Ð, Æó °íÇ÷¾ÐÁõ
  • renal hypertension
    ½Å¼º °íÇ÷¾Ð
  • splenoportal hypertension
    ºñ ¹®¸Æ¼º °íÇ÷¾ÐÁõ
  • clinical application
    ÀÓ»óÀû Àû¿ë
  • clinical chart
    º´»ó ÀÏÁö
  • clinical cytogenetics
    ¼¼Æ÷ À¯ÀüÇÐ
    À¯Àü, Áï ¿°»öü¿Í °ü°èµÈ ¼¼Æ÷ ¿ä¼Ò¸¦ ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÇ ºÐ¾ß.
  • clinical diagnosis
    ÀÓ»ó Áø´Ü, ÀÓ»óÀû Áø´Ü
    Áø´ÜÀº º¸Åë º´·ÂÀ» ûÃëÇÏ°í ½ÅüÀû ¼Ò°ßÀ» ÃëÇϸç Çʿ信 µû¶ó¼­ °Ë»çÇÏ°í ¾òÀº Á¤º¸¸¦ Á¾ÇÕÇØ¼­ ³»·ÁÁö´Â °ÍÀ¸·Î ÀÌ¿Í °°Àº Áø´ÜÀ» ¼ö¼ú ½Ã¿¡ È®ÀÎÇÑ ¼ö¼ú½Ã Áø´Ü, ¶Ç´Â »çÈÄ ºÎ°Ë¿¡ ÀÇÇØ¼­ È®ÀÎµÈ º´¸® Áø´ÜÀ» ´ëºñ½ÃÄѼ­ ÀÓ»ó Áø´ÜÀ̶ó°í ÇÑ´Ù.
  • clinical examination
    ÀÓ»ó °Ë»ç, ÀÓ»ó ÁøÂû, ÀÓ»óÀû °üÂû
  • clinical hematology
    ÀÓ»ó Ç÷¾×ÇÐ
  • clinical interview
    ÀÓ»ó ¸é´ã
  • clinical locking
    ÀÓ»óÀû °úµÎ °É¸²
  • clinical material
    ÀÓ»ó °¡°Ë¹°, ÀÓ»ó °Ëü
  • clinical modification code
    ÀÓ»ó ¼öÁ¤ ºÎÈ£
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
leukaemia, experimental Leukaemia induced experimentally by administration of various leukemogenic agents, viruses, radiation or transplantation.
(12 Dec 1998)
liver neoplasms, experimental Experimentally induced tumours of the liver.
(12 Dec 1998)
accelerated hypertension <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
adrenal hypertension Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex.
(05 Mar 2000)
benign hypertension Hypertension that runs a relatively long and symptomless course.
(05 Mar 2000)
borderline hypertension By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic.
(05 Mar 2000)
pale hypertension Hypertension with pallor of the skin, a severe form with pronounced constriction of peripheral vessels.
(05 Mar 2000)
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
renal hypertension Hypertension secondary to renal disease.
(05 Mar 2000)
renovascular hypertension Hypertension produced by renal arterial obstruction.
(05 Mar 2000)
Goldblatt hypertension Increased blood pressure following obstruction of blood flow to one kidney.
Synonym: Goldblatt phenomenon.
(05 Mar 2000)
portal hypertension Any increase in the portal vein (in the liver) pressure due to anatomic or functional obstruction (for example alcoholic cirrhosis) to blood flow in the portal venous system. Indicators of portal hypertension are: oesophageal varices, haemorrhoids, enlarged veins on the anterior abdominal wall (caput Medusae) and ascites (fluid within the abdominal cavity).
(27 Sep 1997)
portal hypertension: classification <radiology> Presinusoidal, extrahepatic: portal vein obstruction (extrinsic compression, phlebitis, OC, coagulopathy, tumour invasion, pancreatitis, neonatal omphalitis), dynamic: traumatic/neoplastic arterioportal fistula, segmental portal hypertension: splenic/superior mesenteric vein occlusion, intrahepatic (obstruction of portal venules): congenital hepatic fibrosis, primary biliary cirrhosis, sarcoid, myelofibrosis, schistosomiasis, idiopathic noncirrhotic fibrosis, Wilson disease, reticuloendotheliosis, Felty syndrome, chronic malaria, toxic fibrosis (arsenic, copper, PVC vapors) sinusoidal, cirrhosis, sclerosing cholangitis postsinusoidal, Budd-Chiari syndrome, constrictive pericarditis, congestive heart failure
(12 Dec 1998)
postcapillary pulmonary hypertension <radiology> Heart: LV failure, mitral stenosis, LA myxoma / thrombus, cor triatriatum, Pulmonary veins: congenital stenosis of pulmonary vein origin, mediastinal granulomata and neoplasms, idiopathic pulmonary veno-occlusive disease, anomalous pulmonary venous return
(12 Dec 1998)
postpartum hypertension <obstetrics> Increased blood pressure immediately following the completion of labour.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • and so on
    ..µîµî
  • and such
    µûÀ§,µîµî
  • and that
    ±×°Íµµ,°Ô´Ù°¡
  • both ~ and -
    ~ µµ - µµ (µÑ´Ù)
  • by and by
    ÀÌÀ¹°í
  • by-and-by
    ¹Ì·¡
  • checks and balances
    °ßÁ¦¿Í ±ÕÇü
  • every now and then
    À̵û±Ý
  • here and there
    ¿©±âÀú±â¿¡
  • hide-and-go-seek
    ¼û¹Ù²ÀÁú
  • hide-and-seek
    ¼û¹Ù²ÀÁú
  • hole-and-corner
    ºñ¹ÐÀÇ
  • kith and kin
    ģôÁö±â, Àϰ¡Ä£Ã´
  • now and again
    À̵û±Ý
  • now and then
    ¶§¶§·Î (every ... ... ....)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á